PMID- 28821462
OWN - NLM
STAT- MEDLINE
DCOM- 20180723
LR  - 20180723
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 267
DP  - 2017 Dec 10
TI  - Ferritin nanocage with intrinsically disordered proteins and affibody: A platform 
      for tumor targeting with extended pharmacokinetics.
PG  - 172-180
LID - S0168-3659(17)30781-2 [pii]
LID - 10.1016/j.jconrel.2017.08.014 [doi]
AB  - Ferritin nanocages are of particular interest as a novel platform for drug and 
      vaccine delivery, diagnosis, biomineralization scaffold and more, due to their 
      perfect and complex symmetry, ideal physical properties, high biocompatibility, 
      low toxicity profiles as well as easy manipulation by genetic or chemical 
      strategies. However, a short half-life is still a hurdle for the translation of 
      ferritin-based nanomedicines into the clinic. Here, we developed a series of 
      rationally designed long circulating ferritin nanocages (LCFNs) with 
      'Intrinsically Disordered Proteins (IDP)' as a stealth layer for extending the 
      half-life of ferritin nanocages. Through predictions with 3D modelling, the LCFNs 
      were designed, generated and their pharmacokinetic parameters including 
      half-life, clearance rate, mean residence time, and more, were evaluated by 
      qualitative and quantitative analysis. LCFNs have a tenfold increased half-life 
      and overall improved pharmacokinetic parameters compared to wild-type ferritin 
      nanocages (wtFN), corresponding to the low binding against bone marrow-derived 
      macrophages (BMDMs) and endothelial cells. Subsequently, a tumor targeting 
      moiety, epidermal growth factor receptor (EGFR)-targeting affibody peptide, was 
      fused to LCFNs for evaluating their potential as a theragnostic platform. The 
      tumor targeting-LCFNs successfully accumulated to the tumor tissue, by efficient 
      targeting via active and passive properties, and also the shielding effect of IDP 
      in vivo. This strategy can be applied to other protein-based nanocages for 
      further progressing their use in the field of nanomedicine.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Lee, Na Kyeong
AU  - Lee NK
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; 
      Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul 
      National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea.
FAU - Lee, Eun Jung
AU  - Lee EJ
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; 
      Department of Chemical Engineering, School of Applied Chemical Engineering, 
      Kyungpook National University, Daegu 41566, Republic of Korea.
FAU - Kim, Soyoun
AU  - Kim S
AD  - Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, 
      School of Medicine, Kyungpook National University, Daegu 41566, Republic of 
      Korea.
FAU - Nam, Gi-Hoon
AU  - Nam GH
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; 
      KU-KIST Graduate School of Converging Science and Technology, Korea University, 
      145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
FAU - Kih, Minwoo
AU  - Kih M
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; 
      KU-KIST Graduate School of Converging Science and Technology, Korea University, 
      145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
FAU - Hong, Yeonsun
AU  - Hong Y
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; 
      KU-KIST Graduate School of Converging Science and Technology, Korea University, 
      145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.
FAU - Jeong, Cherlhyun
AU  - Jeong C
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
FAU - Yang, Yoosoo
AU  - Yang Y
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea.
FAU - Byun, Youngro
AU  - Byun Y
AD  - Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul 
      National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea; 
      Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School 
      of Convergence Science and Technology, Seoul National University, 1 Gwanak-ro, 
      Gwanak-gu, Seoul 08826, Republic of Korea. Electronic address: yrbyun@snu.ac.kr.
FAU - Kim, In-San
AU  - Kim IS
AD  - Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science 
      and Technology, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea; 
      KU-KIST Graduate School of Converging Science and Technology, Korea University, 
      145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. Electronic address: 
      iskim14@kist.re.kr.
LA  - eng
PT  - Journal Article
DEP - 20170815
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Intrinsically Disordered Proteins)
RN  - 0 (Peptides)
RN  - 9007-73-2 (Ferritins)
SB  - IM
MH  - Animals
MH  - *Drug Delivery Systems
MH  - Ferritins/*administration & dosage/chemistry/pharmacokinetics
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Intrinsically Disordered Proteins/*administration & 
      dosage/chemistry/pharmacokinetics
MH  - Macrophages/drug effects/metabolism
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Microscopy, Electron, Transmission
MH  - Nanostructures/*administration & dosage/chemistry/ultrastructure
MH  - Neoplasms/*metabolism
MH  - Peptides/*administration & dosage/chemistry/pharmacokinetics
OTO - NOTNLM
OT  - Ferritin nanocages
OT  - Half-life
OT  - Intrinsically disordered protein
OT  - Nanomedicine
OT  - Pharmacokinetics
EDAT- 2017/08/20 06:00
MHDA- 2018/07/24 06:00
CRDT- 2017/08/20 06:00
PHST- 2017/05/06 00:00 [received]
PHST- 2017/08/12 00:00 [revised]
PHST- 2017/08/14 00:00 [accepted]
PHST- 2017/08/20 06:00 [pubmed]
PHST- 2018/07/24 06:00 [medline]
PHST- 2017/08/20 06:00 [entrez]
AID - S0168-3659(17)30781-2 [pii]
AID - 10.1016/j.jconrel.2017.08.014 [doi]
PST - ppublish
SO  - J Control Release. 2017 Dec 10;267:172-180. doi: 10.1016/j.jconrel.2017.08.014. 
      Epub 2017 Aug 15.